Moksha8 Launches Broad Product Portfolio in Key Emerging Markets
– Strategic Alliances with Roche and Pfizer Provide Portfolio of Over 20 Products –
Hong Kong, Sao Paulo, Shanghai, Philadelphia, PA –April 16, 2008 /PR Newswire
moksha8, Inc. announced today strategic partnerships with Roche and Pfizer, the launch of over twenty products and establishment of its Latin America headquarters in Sao Paulo, Brazil. moksha8 is committed to providing the highest quality medicine to the fastest growing markets of the world, with an initial focus on Asia, Latin America and Eastern Europe.
In February 2008, moksha8 established strategic alliances with Roche and Pfizer in four therapeutic areas, CNS disease, anti-infectives, cardiovascular disease and pain management. The initial Roche and Pfizer portfolios consist of more than 20 products, including Neurontin®, Lexotan®, Zoloft®, and Bactrim®
Moksha8 has established its Latin American headquarters in Sao Paulo, Brazil and has built a fully integrated sales and marketing team to drive the launch and commercialization of this comprehensive first line of products. Current annual sales of these products in Brazil are estimated to be over $80 million USD.
Moksha8 was founded in December 2006 by Simba Gill and TPG and has raised significant financing from top-tier private equity firms, including TPG and Votorantim Novos Negocios, the venture capital and private equity arm of Votorantim, one of Brazil’s largest privately held conglomerates. Moksha8 is uniquely positioned as the partner of choice for both pharmaceutical and biotechnology companies seeking to capture value from their products in high growth emerging markets. Moksha8 has established commercial operations in key geographies in Asia and Latin America with Corporate offices in Hong Kong and Philadelphia.
Moksha8 provides the highest quality medicines to the fastest growing markets of the world.